News Releases
|
First Quarter Financial Results1 |
|||||||||||||||
|
|
Three Months Ended |
||||||||||||||
| (Millions, except per share results) | 2015 | 2014 |
Increase/ |
||||||||||||
| Net Revenue | $ | 981.0 | $ | 966.5 | 1.5 | % | |||||||||
|
Segment Profit2 |
64.9 | 76.5 | (15.2 | %) | |||||||||||
| Net Income | 7.3 | 25.7 | (71.6 | %) | |||||||||||
|
Adjusted Net Income3 |
24.4 | 27.3 | (10.6 | %) | |||||||||||
| Earnings per Share | 0.28 | 0.92 | (69.6 | %) | |||||||||||
| Adjusted Earnings per Share3 | 0.94 | 0.97 | (3.1 | %) | |||||||||||
- The increase in revenue between periods resulted primarily from the impact of new business, same store growth and rate increases, and the inclusion of revenues from CDMI in the current year, which were partially offset by the loss of revenues associated with previously announced contract terminations.
- The decrease in segment profit between periods is primarily due to previously announced contract terminations, which were partially offset by new business, same store growth and the inclusion of CDMI results in the current year quarter.
- The decrease in net income is primarily due to the decrease in segment profit and non-cash expenses relating to acquisitions, comprised of
$15.0 million of changes in the fair value of contingent consideration,$7.4 million of higher stock compensation expense, and$2.8 million of incremental amortization of acquired intangibles, offset by the tax impact of such items. The majority of the increase in the fair value of contingent consideration is due to an improved outlook for CDMI, resulting in increased estimates of the performance-related earn-outs. - The decrease in adjusted net income between periods was mainly due to decreased segment profit.
As of
"This year is off to a promising start, and we are well-positioned for future growth," said
Results and Outlook
"I'm pleased with our solid financial results in the quarter, as well as with our continued progress in executing on our growth strategy, including the successful acquisition of 4D Pharmacy Management Systems. 4D serves to further strengthen our growing pharmacy business," said
"4D is expected to generate revenues during the last nine months of 2015 of
"Relative to full year 2015, we are updating our guidance to reflect the impact of the 4D and HSM acquisitions, as well as the increase in the fair value of CDMI contingent consideration and share repurchase activity. We now expect revenue of
Earnings Conference Call
Management will host a conference call at
About
Cautionary Statement
This release contains forward‐looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward‐looking statements including, without limitation, statements regarding estimates of 2015 net revenue, net income, changes in fair value of contingent consideration, adjusted net income, segment profit, cash flow from operations, earnings per share, adjusted earnings per share, the results of the 4D acquisition, and capital deployment, growth and strategy. These statements are based on management's analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "may," "should," "could," "estimate," "intend" and other similar expressions are intended to identify forward‐looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company's customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company's risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for
1 Included in the tables issued with this press release are the reconciliations from non-GAAP measures to the corresponding GAAP measures.
2 Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, as well as stock compensation expense and changes in the fair value of contingent consideration recorded in relation to acquisitions.
3 Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands, except per share amounts) | ||||||||||||
| Three Months Ended | ||||||||||||
| 2014 |
2015 (1) |
|||||||||||
| Net revenue: | ||||||||||||
| Managed care and other | $ | 829,591 | $ | 748,650 | ||||||||
| PBM and dispensing | 136,884 | 232,318 | ||||||||||
| Total net revenue | 966,475 | 980,968 | ||||||||||
| Costs and expenses: | ||||||||||||
| Cost of care | 605,708 | 522,328 | ||||||||||
| Cost of goods sold | 125,298 | 218,207 | ||||||||||
| Direct service costs and other operating expenses (2)(3) | 164,722 | 204,450 | ||||||||||
| Depreciation and amortization | 20,229 | 23,496 | ||||||||||
| Interest expense | 836 | 1,626 | ||||||||||
| Interest income | (311 | ) | (466 | ) | ||||||||
| Total costs and expenses | 916,482 | 969,641 | ||||||||||
| Income before income taxes | 49,993 | 11,327 | ||||||||||
| Provision for income taxes | 25,613 | 4,133 | ||||||||||
| Net income | 24,380 | 7,194 | ||||||||||
| Less: net income (loss) attributable to non-controlling interest | (1,340 | ) | (94 | ) | ||||||||
| Net income attributable to |
$ | 25,720 | $ | 7,288 | ||||||||
| Weighted average number of common shares outstanding — Basic | 27,370 | 25,319 | ||||||||||
| Weighted average number of common shares outstanding — Diluted | 28,051 | 26,399 | ||||||||||
| Net income per common share attributable to |
$ | 0.94 | $ | 0.29 | ||||||||
| Net income per common share attributable to |
$ | 0.92 | $ | 0.28 | ||||||||
| Net income | $ | 24,380 | $ | 7,194 | ||||||||
| Other comprehensive income: | ||||||||||||
| Unrealized gains on available-for-sale securities (4) | 43 | 69 | ||||||||||
| Comprehensive income | 24,423 | 7,263 | ||||||||||
| Less: comprehensive income (loss) attributable to non-controlling interest | (1,340 | ) | (94 | ) | ||||||||
| Comprehensive income attributable to |
$ | 25,763 | $ | 7,357 | ||||||||
(1) For a more detailed discussion of
(2) Includes stock compensation expense of
(3) Includes changes in fair value of contingent consideration of
(4) Net of income tax provision of
| NON-GAAP MEASURES | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands, except per share amounts) | ||||||||||||
| Three Months Ended | ||||||||||||
| 2014 |
2015 (1) |
|||||||||||
| Adjusted Net Income | $ | 27,306 | $ | 24,384 | ||||||||
| Adjusted for acquisitions starting in 2013 | ||||||||||||
| Stock compensation relating to acquisitions | (939 | ) | (8,338 | ) | ||||||||
| Changes in fair value of contingent consideration | - | (14,969 | ) | |||||||||
| Amortization of acquired intangibles | (1,633 | ) | (4,383 | ) | ||||||||
| Tax impact | 986 | 10,594 | ||||||||||
| Net income attributable to |
$ | 25,720 | $ | 7,288 | ||||||||
| Adjusted EPS | $ | 0.97 | $ | 0.94 | ||||||||
| Adjusted for acquisitions starting in 2013 | ||||||||||||
| Stock compensation relating to acquisitions | (0.03 | ) | (0.32 | ) | ||||||||
| Changes in fair value of contingent consideration | - | (0.57 | ) | |||||||||
| Amortization of acquired intangibles | (0.06 | ) | (0.17 | ) | ||||||||
| Tax impact | 0.04 | 0.40 | ||||||||||
| Net income per common share attributable to |
$ | 0.92 | $ | 0.28 | ||||||||
(1) The Company's Quarterly Report on Form 10-Q for the three months ended
| CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands) | ||||||||||||
| Three Months Ended | ||||||||||||
| 2014 |
2015 (1) |
|
||||||||||
| Cash flows from operating activities: | ||||||||||||
| Net income | $ | 24,380 | $ | 7,194 | ||||||||
| Adjustments to reconcile net income to net cash provided by | ||||||||||||
| operating activities: | ||||||||||||
| Depreciation and amortization | 20,229 |
|
23,496 | |||||||||
| Non-cash interest expense | 184 | 99 | ||||||||||
| Non-cash stock compensation expense | 4,472 | 13,901 | ||||||||||
| Non-cash income tax benefit | (3,733 | ) | (2,263 | ) | ||||||||
| Non-cash amortization on investments | 1,611 | 1,539 | ||||||||||
| Cash flows from changes in assets and liabilities, net of effects | ||||||||||||
| from acquisitions of businesses: | ||||||||||||
| Restricted cash (2) | (27,870 | ) | 9,739 | |||||||||
| Accounts receivable, net | 34,843 | 1,425 | ||||||||||
| Pharmaceutical inventory | 2,504 | 4,770 | ||||||||||
| Other assets | (17,273 | ) | (27,219 | ) | ||||||||
| Accounts payable and accrued liabilities | 30,344 | (22,398 | ) | |||||||||
| Medical claims payable and other medical liabilities | 9,803 | 23,663 | ||||||||||
| Tax contingencies | 801 | (787 | ) | |||||||||
| Deferred credits and other long-term liabilities | 2,533 | 11,000 | ||||||||||
| Other | (1 | ) | (3 | ) | ||||||||
| Net cash provided by operating activities | 82,827 | 44,156 | ||||||||||
| Cash flows from investing activities: | ||||||||||||
| Capital expenditures | (11,059 | ) | (21,396 | ) | ||||||||
| Acquisitions and investments in businesses, net of cash acquired | - | (13,640 | ) | |||||||||
| Purchase of investments | (76,548 | ) | (128,851 | ) | ||||||||
| Maturity of investments | 74,424 | 92,499 | ||||||||||
| Net cash used in investing activities | (13,183 | ) | (71,388 | ) | ||||||||
| Cash flows from financing activities: | ||||||||||||
| Payments to acquire treasury stock | (16,970 | ) | (32,112 | ) | ||||||||
| Proceeds from exercise of stock options and warrants | 7,180 | 36,900 | ||||||||||
| Payments on long-term debt and capital lease obligations | (1,117 | ) | (3,662 | ) | ||||||||
| Tax benefit from exercise of stock options and vesting of stock awards | 517 | 2,961 | ||||||||||
| Other | (1,141 | ) | (807 | ) | ||||||||
| Net cash (used in) provided by financing activities | (11,531 | ) | 3,280 | |||||||||
| Net increase (decrease) in cash and cash equivalents | 58,113 | (23,952 | ) | |||||||||
| Cash and cash equivalents at beginning of period | 203,187 | 255,303 | ||||||||||
| Cash and cash equivalents at end of period | $ | 261,300 | $ | 231,351 | ||||||||
(1) The Company's Quarterly Report on Form 10-Q for the three months ended
(2) Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the three months ended
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands) | ||||||||||||
| Three Months Ended | ||||||||||||
| 2014 |
2015 (1) |
|||||||||||
| Managed care and other revenue | ||||||||||||
| - Commercial | $ | 188,891 | $ | 152,525 | ||||||||
| - Public Sector | 497,943 | 422,977 | ||||||||||
| - Specialty Solutions | 105,434 | 124,342 | ||||||||||
| - Pharmacy Management (2) | 55,378 | 49,068 | ||||||||||
| - Elimination (2) | (18,055 | ) | (262 | ) | ||||||||
| Total managed care and other revenue | 829,591 | 748,650 | ||||||||||
| PBM and dispensing revenue | ||||||||||||
| - Pharmacy Management (2) | 139,624 | 258,793 | ||||||||||
| - Elimination (2) | (2,740 | ) | (26,475 | ) | ||||||||
| Total PBM and dispensing revenue | 136,884 | 232,318 | ||||||||||
| Cost of care | ||||||||||||
| - Commercial | 111,202 | 82,130 | ||||||||||
| - Public Sector (2) | 422,518 | 346,930 | ||||||||||
| - Specialty Solutions | 73,652 | 93,273 | ||||||||||
| - Pharmacy Management | 16,391 | (5 | ) | |||||||||
| - Elimination (2) | (18,055 | ) | - | |||||||||
| Total cost of care | 605,708 | 522,328 | ||||||||||
| Cost of goods sold | ||||||||||||
| - Pharmacy Management (2) | 128,031 | 243,538 | ||||||||||
| - Elimination (2) | (2,733 | ) | (25,331 | ) | ||||||||
| Total cost of goods sold | 125,298 | 218,207 | ||||||||||
| Direct service costs and other operating expenses | ||||||||||||
| - Commercial | 40,276 | 39,210 | ||||||||||
| - Public Sector | 42,958 | 51,387 | ||||||||||
| - Specialty Solutions | 15,141 | 20,174 | ||||||||||
| - Pharmacy Management | 35,551 | 63,548 | ||||||||||
| - Corporate | 30,803 | 31,537 | ||||||||||
| - Elimination (2) | (7 | ) | (1,406 | ) | ||||||||
| Total direct service costs and other operating expenses | 164,722 | 204,450 | ||||||||||
| Stock compensation expense (3) | ||||||||||||
| - Commercial | (155 | ) | (171 | ) | ||||||||
| - Public Sector | (274 | ) | (309 | ) | ||||||||
| - Specialty Solutions | (414 | ) | (509 | ) | ||||||||
| - Pharmacy Management | (303 | ) | (8,856 | ) | ||||||||
| - Corporate | (3,326 | ) | (4,056 | ) | ||||||||
| Total stock compensation expense | (4,472 | ) | (13,901 | ) | ||||||||
| Changes in fair value of contingent consideration (3) | ||||||||||||
| - Commercial | - | (100 | ) | |||||||||
| - Pharmacy Management | - | (14,869 | ) | |||||||||
| Total changes in fair value of contingent consideration | - | (14,969 | ) | |||||||||
| Less: non-controlling interest segment profit (loss) (4) | ||||||||||||
| - Public Sector | (1,330 | ) | (120 | ) | ||||||||
| - Corporate | - | 26 | ||||||||||
| Total non-controlling interest segment profit (loss) | (1,330 | ) | (94 | ) | ||||||||
| Segment profit (loss) | ||||||||||||
| - Commercial | 37,568 | 31,456 | ||||||||||
| - Public Sector | 34,071 | 25,089 | ||||||||||
| - Specialty Solutions | 17,055 | 11,404 | ||||||||||
| - Pharmacy Management | 15,332 | 24,505 | ||||||||||
| - Corporate and Elimination | (27,477 | ) | (27,507 | ) | ||||||||
| Total segment profit | $ | 76,549 | $ | 64,947 | ||||||||
| Reconciliation of segment profit to income before income taxes: | ||||||||||||
| Segment profit | $ | 76,549 | $ | 64,947 | ||||||||
| Stock compensation expense | (4,472 | ) | (13,901 | ) | ||||||||
| Changes in fair value of contingent consideration | - | (14,969 | ) | |||||||||
| Non-controlling interest segment profit (loss) | (1,330 | ) | (94 | ) | ||||||||
| Depreciation and amortization | (20,229 | ) | (23,496 | ) | ||||||||
| Interest expense | (836 | ) | (1,626 | ) | ||||||||
| Interest income | 311 | 466 | ||||||||||
| Income before income taxes | $ | 49,993 | $ | 11,327 | ||||||||
(1) The Company's Quarterly Report on Form 10-Q for the three months ended
(2) Public Sector subcontracts with Pharmacy Management and Specialty Solutions to provide pharmacy benefits management services and radiology benefits management services for certain of Public Sector's customers. In addition, Pharmacy provides pharmacy benefits management for the Company's employees covered under its medical plan. As such, revenue, cost of care, cost of goods sold and direct service costs and other related to these arrangements are eliminated.
(3) Stock compensation expense and changes in fair value of contingent consideration are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit.
(4) The non-controlling interest portion of AlphaCare's segment profit (loss) is excluded from the computation of segment profit.
Magellan Health, Inc.
Media:
cefjohnson@magellanhealth.com
or
Investors:
rshapiro@magellanhealth.com
Source:
News Provided by Acquire Media
